hIL23A/hTL1A(3)
Nomenclature
C57BL/6JSmo-Tnfsf15tm1(hTNFSF15)Il23atm3(hIL23A)Smoc
Cat. NO.
NM-XA-241237
Strain State
Repository Live
Gene Summary
Gene Symbol
Il23a
Model Description
Validation Data
Fig.1 In Vivo Efficacy of Risankizumab and Duvakitug combo in TBNS-induced acute colitis in Humanized hIL23A/hTL1A(3) Mouse Model
(A) Body weight change and (B) DAI score in the TBNS-induced acute colitis model of hIL23A/hTL1A(3) mice. In this study, all hIL23A/hTL1A(3) mice were randomly divided into experimental and control cohorts groups on Day -1. The acute colitis model was established in hIL23A/hTL1A(3) mice by a single intrarectal injection of 1.5% TNBS on Day 0. Body weight and DAI score were recorded daily. (n=4-5 males per group, 9-10 weeks old, Mean ± SEM, one-way ANOVA followed by Dunnett's multiple comparison test, *P<0.05, **P<0.01, ***P<0.0001)
Fig.2 In Vivo Efficacy of Risankizumab and Duvakitug combo in TBNS-induced acute colitis in hIL23A/hTL1A(3) Mouse Model.
(A) Colon length. (B) Colon weight. (C）Colon index. On Day 5, all mice were sacrificed, and the isolated colons were subjected to weight, length and photograph. The results demonstrated that, compared with the control group, combo treatment groups exhibited a significant amelioration of TBNS-induced acute colitis in hIL23A/hTL1A(3) mice. (n=4-5 males per group, 9-10 weeks old, Mean ± SEM, one-way ANOVA followed by Dunnett's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)
Fig.3 In Vivo Efficacy of Risankizumab and Duvakitug combo in TBNS-induced acute colitis in hIL23A/hTL1A(3) Mouse Model.
Colon photo. On Day 5, all mice were sacrificed, and the isolated colons were subjected to weight and photograph. The results demonstrated that, compared with the control group, treatment groups exhibited a significant amelioration of TBNS-induced acute colitis in hTL1A mice. (n=4-5 males per group, 9-10 weeks old)
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn moreMilestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more
